How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Thoracic Endovascular Aneurysm Repair (TEVAR) Market
- By Device Type: Thoracic Stent Grafts, Hybrid Graft Systems, Fenestrated and Branched Stent Grafts, Custom-made Stent Grafts
- By Aneurysm Type: Thoracic Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Dissection, Traumatic Aortic Injury
- By Access Route: Femoral Artery Access, Axillary Artery Access, Transapical Access, Direct Aortic Access
- By End User: Hospitals, Specialized Vascular Clinics, Ambulatory Surgical Centers
- By Procedure Type: Elective TEVAR Procedures, Emergency TEVAR Procedures
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Thoracic Stent Grafts leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.172 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.180 →
Full report · locked preview
Everything inside the Thoracic Endovascular Aneurysm Repair (TEVAR) Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Device Type 4
Aneurysm Type 4
Access Route 4
End User 3
Procedure Type 2
Companies profiled
Medtronic
Terumo Corporation
W.L. Gore & Associates
Cook Medical
Endologix (now part of Terumo)
Becton Dickinson (BD)
C.R. Bard (now part of BD)
Bolton Medical (a subsidiary of Terumo)
Jotec GmbH (a subsidiary of CryoLife)
Vascutek (a Terumo company)
Cardinal Health
Abbott Laboratories
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →W.L. Gore & Associates
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cook Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Endologix (now part of Terumo)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Becton Dickinson (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →C.R. Bard (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bolton Medical (a subsidiary of Terumo)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jotec GmbH (a subsidiary of CryoLife)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vascutek (a Terumo company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cardinal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Abbott Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Stryker Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Philips Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Siemens Healthineers
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$781.2M by 2033 · 7.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Thoracic Stent Grafts60.9
- Hybrid Graft Systems15.4
- Fenestrated and Branched Stent Grafts7.5
- Custom-made Stent Grafts16.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$148.2M → $286.2M · 8.6%
Europe$103.3M → $196.6M · 8.4%
Asia Pacific$94.3M → $175.4M · 8.1%
Latin America$58.4M → $92.7M · 5.9%
Middle East and Africa$44.9M → $75.5M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.132026
7.132027
7.152028
7.172029
7.162030
7.182031
7.182032
7.202033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic24.8
- Terumo Corporation13.1
- W.L. Gore & Associates6.2
- Cook Medical12.5
- Endologix (now part of Terumo)5.6
- Becton Dickinson (BD)9.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type26.5%
Aneurysm Type17.8%
Access Route27.8%
End User14.0%
Procedure Type14.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.6
- Europe23.8
- Asia Pacific21.2
- Latin America11.2
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 98 | 82 | 91 | 75 | 96 | 76 | 86 |
| Terumo Corporation | 91 | 74 | 82 | 88 | 81 | 87 | 84 |
| W.L. Gore & Associates | 75 | 82 | 65 | 70 | 87 | 88 | 78 |
| Cook Medical | 77 | 82 | 65 | 70 | 80 | 73 | 75 |
| Endologix (now part of Terumo) | 76 | 69 | 53 | 52 | 61 | 70 | 64 |
| Becton Dickinson (BD) | 56 | 64 | 63 | 47 | 57 | 66 | 59 |
| C.R. Bard (now part of BD) | 51 | 60 | 48 | 62 | 49 | 56 | 54 |
| Bolton Medical (a subsidiary of Terumo) | 43 | 50 | 56 | 55 | 39 | 44 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Terumo Corporation
- W.L. Gore & Associates
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Terumo Corporation | ✓ | ◐ | ✓ | ◐ | ✓ | ✓ |
| W.L. Gore & Associates | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Cook Medical | ◐ | ✓ | ✓ | ◐ | ◐ | − |
| Endologix (now part of Terumo) | ✓ | − | − | ◐ | ◐ | ✓ |
| Becton Dickinson (BD) | ◐ | ◐ | − | − | ◐ | ◐ |
| C.R. Bard (now part of BD) | − | ◐ | ◐ | − | − | ◐ |
| Bolton Medical (a subsidiary of Terumo) | ◐ | − | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic86
2Terumo Corporation84
3W.L. Gore & Associates78
4Cook Medical75
5Endologix (now part of Terumo)64
6Becton Dickinson (BD)59
7C.R. Bard (now part of BD)54
8Bolton Medical (a subsidiary of Terumo)48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
MedtronicTerumo CorporationW.L. Gore & Associates
Challenger1
Strong scale, closing on the leaders.
Cook Medical
Contender2
Focused players with pockets of strength.
Endologix (now part of Terumo)Becton Dickinson (BD)
Niche2
Specialists in a single segment or region.
C.R. Bard (now part of BD)Bolton Medical (a subsidiary of Terumo)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Device Type in North America, then scale across Thoracic Endovascular Aneurysm Repair (TEVAR) Market — a $462M beachhead inside a $7.31B market.
Beachhead (SOM)$462Mobtainable near-term
Serviceable (SAM)$2.54Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Thoracic Stent Grafts
Best fit — highest urgency & budget in Device Type.
Economic buyer78 fit
Hybrid Graft Systems
Strong fit — clear ROI and a fast path to value.
End user66 fit
Fenestrated and Branched Stent Grafts
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Aneurysm Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Access Route
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Thoracic Endovascular Aneurysm Repair (TEVAR) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified26%
Evaluation11%
Closed-won6%
$17.6KCAC
$97KLTV
5.5:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Thoracic Endovascular Aneurysm Repair (TEVAR) Market is a resilient opportunity — $3.63B by 2033, compounding at 5.6%.
TAM · 2025$2.34Btoday
TAM · 2033$3.63Bforecast
CAGR5.6%2027–2033
Cumulative$26.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.63BTotal addressable market
SAM$1.49BServiceable available market
SOM$256MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.6% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.63BLarge & growingTAM by 2033 at 5.6% CAGR
$1.49BServiceable nowreachable with today’s model
$256MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.83BBear3.7% CAGR
$3.63BBase5.6% CAGR
$4.65BBull7.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Aneurysm Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Thoracic Endovascular Aneurysm Repair (TEVAR) Market — a $6.54B market by 2033. Plan: grow share from 9.2% to 16.5%.
Market size · 2033$6.54Btotal addressable
Market CAGR6.4%2027–2033
Target share16.5%from 9.2% today
Revenue ambition$1.08Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.2% | 16.5% | On track |
| Revenue | $606M | $1.08B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.2% | 38.3% | Behind |
| Customer retention | 86.3% | 96.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Aneurysm Type capability
A defensible second engine — invest in Aneurysm Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Aneurysm Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $115M capacity & capability investment
- Greenlight bolt-on M&A in Aneurysm Type
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Thoracic Endovascular Aneurysm Repair (TEVAR) Market conversation — a $10.5B market you can size, segment and defend in minutes.
Market size · 2033$10.5Btotal opportunity
Growth9.3%CAGR to 2033
Addressable buyers1,102+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 3 mopayback period
$70K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
MedtronicTerumo CorporationW.L. Gore & AssociatesCook MedicalEndologix (now part of Terumo)Becton Dickinson (BD)C.R. Bard (now part of BD)Bolton Medical (a subsidiary of Terumo)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Thoracic Endovascular Aneurysm Repair (TEVAR) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Thoracic Endovascular Aneurysm Repair (TEVAR) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Thoracic Endoprosthesis Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportThoracic Drainage Catheters Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThoracic Biomesh Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportThoracic Aortic Stent System Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportThoracic Aortic Stent Graft System (TAA Stent Graft System) Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThoracic Aortic Graft Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThoracic Aortic Covered Stents Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThoracic Aorta Stent Graft Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportThoracic Aorta Covered Stent Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThird-party Testing Agency Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThird-Party Medical Testing Laboratory Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThird-party Medical Inspection Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.